GILD Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
8.3B
+6.4%
7.8B
+12.1%
7.0B
-12.2%
7.9B
+2.0%
7.8B
Cost of Revenue
1.6B
-0.5%
1.6B
+9.3%
1.4B
-11.0%
1.6B
+3.5%
1.6B
Gross Profit
6.7B
+8.1%
6.2B
+12.9%
5.5B
-12.5%
6.3B
+1.6%
6.2B
Operating Expenses
3.3B
-80.3%
16.6B
+467.2%
2.9B
-32.1%
4.3B
+50.3%
2.9B
R&D
1.6B
-87.4%
12.9B
+843.7%
1.4B
-13.4%
1.6B
+4.5%
1.5B
SG&A
1.6B
-14.6%
1.9B
+32.4%
1.5B
-19.1%
1.8B
+32.2%
1.4B
Operating Income
3.5B
+133.3%
-10394000000
-502.1%
2.6B
+30.3%
2.0B
-40.4%
3.3B
EBITDA
4.2B
+152.9%
-7946000000
-335.0%
3.4B
-6.3%
3.6B
-10.0%
4.0B
Net Income
2.4B
+123.1%
-10496000000
-619.3%
2.0B
-7.4%
2.2B
-28.5%
3.1B
EPS (Basic)
$1.96
+123.2%
$-8.45
-618.4%
$1.63
-7.4%
$1.76
-28.5%
$2.46
EPS (Diluted)
$1.94
+123.0%
$-8.45
-624.8%
$1.61
-7.5%
$1.74
-28.4%
$2.43
Shares (Diluted)
1.3B
+0.6%
1.2B
-0.9%
1.3B
+0.2%
1.3B
-0.2%
1.3B
Gilead Sciences (GILD) — Financials